Media Articles Related to Acanya (Benzoyl Peroxide / Clindamycin)
Galderma receives FDA approval for new antibiotic-free treatment option for acne patients
Source: Dermatology News From Medical News Today [2015.07.20]
Galderma Laboratories, L.P. has announced that the U.S. Food and Drug Administration (FDA) approved antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.
Nanoparticles used to prevent inflammatory acne through slow-released nitric oxide
Source: Dermatology News From Medical News Today [2015.07.16]
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
Acne Pictures Slideshow: Quick Cover-ups, Do's and Don'ts
Source: MedicineNet Acne Specialty [2015.06.26]
Title: Acne Pictures Slideshow: Quick Cover-ups, Do's and Don'ts
Created: 8/1/2012 12:00:00 AM
Last Editorial Review: 6/26/2015 12:00:00 AM
Could a Vitamin Play a Role in Acne Outbreaks?
Source: MedicineNet Acne Specialty [2015.06.25]
Title: Could a Vitamin Play a Role in Acne Outbreaks?
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM
Acne patients: 'substantial proportion' fail to collect prescribed treatment
Source: Compliance News From Medical News Today [2015.03.22]
Dermatologist-prescribed treatments are being left on pharmacy shelves by up to a quarter of people with acne, according to a new study.
Published Studies Related to Acanya (Benzoyl Peroxide / Clindamycin)
Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel:
efficacy and tolerability of treatment in moderate to severe acne. 
efficacy of acne medications in skin of color... CONCLUSIONS: Acne subjects with Fitzpatrick skin types IV-VI were not found to be
Treatment of moderate to severe acne vulgaris in a Hispanic population: a
post-hoc analysis of efficacy and tolerability of clindamycin phosphate
1.2%/benzoyl peroxide 2.5% gel. 
in Hispanics... CONCLUSIONS: Overall efficacy and tolerability with clindamycin phosphate
Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. [2011.11]
BACKGROUND: Topical therapy with comedolytics and antibiotics are often advocated for mild and moderate severity acne vulgaris. Nadifloxacin, a new fluoroquinolone with anti-Propionibacterium acnes activity and additional anti-inflammatory activity, is approved for use in acne. This randomized controlled assessor blind trial compared the clinical effectiveness and safety of eight weeks therapy of nadifloxacin 1% versus clindamycin 1% as add-on therapy to benzoyl peroxide (2.5%) in mild to moderate grade acne... CONCLUSIONS: Topical nadifloxacin, a new fluoroquinolone is effective, tolerable, and safe for mild o moderate facial acne. Its clinical effectiveness is comparable to clindamycin when used as add-on therapy to benzoyl peroxide.
Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, doubleblind, placebo-controlled trial. [2011.02]
BACKGROUND: Progressive macular hypomelanosis is a dermatosis without definite etiology. There is no consensus or first-line therapy in the treatment of progressive macular hypomelanosis, and the treatment options used are very little effective. OBJECTIVE: To evaluate the therapeutic efficacy of the topical combination of benzoyl peroxide 5% and clindamycin 1% associated with sun exposure for the treatment of progressive macular hypomelanosis... CONCLUSION: The topical combination of benzoyl peroxide 5% and clindamycin 1% is effective in the treatment of progressive macular hypomelanosis.
Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the
treatment of progressive macular hypomelanosis: a randomized, doubleblind,
placebo-controlled trial. [Article in English, Portuguese] 
treatment of progressive macular hypomelanosis... CONCLUSION: The topical combination of benzoyl peroxide 5% and clindamycin 1% is
Clinical Trials Related to Acanya (Benzoyl Peroxide / Clindamycin)
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya´┐Ż Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris [Recruiting]
The objective of this study is to compare the safety and efficacy profiles of Taro
Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1. 2%/2. 5% to Acanya«
(Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1. 2%/2. 5% and to demonstrate the superior
efficacy of the two active formulations over that of the vehicle in the treatment of acne
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac´┐Ż Topical Gel in the Treatment of Acne Vulgaris [Recruiting]
The objective of this study is to compare the relative efficacy and safety of the test
formulation Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to
the marketed formulation Duac« Topical Gel (Clindamycin 1%/Benzoyl Peroxide 5%) (Stiefel) in
the treatment of the inflamed lesions of acne vulgaris. Both the test and reference
formulations will also be compared to a placebo formulation to test for superiority.
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC´┐Ż Gel [Recruiting]
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo
Controlled, Three Arm Clinical Study.
The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate
1. 2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC« Gel of
Stiefel Laboratories)in the ratio of 2: 2:1 of Test drug, Reference drug and Placebo
Total study duration will be for a period of 78 days which includes treatment duration of 77
850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria
mentioned in the protocol.
Comparing OTC Acne Treatment to Prescription Regimen [Recruiting]
This research is being done to find out the safety and efficacy of two acne creams, Effaclar
and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are FDA
approved for the treatment of acne.
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne [Recruiting]
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the
study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin
and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face
fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. After
visit 3, subjects will commence application of clindamycin and benzoyl peroxide gel to the
entire face for an additional 6 weeks.